Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/124332
Title: | A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients |
Author: | Laquente, Berta Lopez Martin, Jose Richards, Donald Illerhaus, Gerald Chang, David Z. Kim, George Stella, Philip Richel, Dirk Szcylik, Cezary Cascinu, Stefano Frassineti, G. L. Ciuleanu, Tudor Hurt, Karla Hynes, Scott Lin, Ji Lin, Aimee Bence Hoff, Daniel Von Calvo, Emiliano |
Keywords: | Càncer de pàncrees Quimioteràpia Pancreas cancer Chemotherapy |
Issue Date: | 14-Feb-2017 |
Publisher: | BioMed Central |
Abstract: | Background: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. Methods: Patients with Stage II-IV locally advanced or metastatic pancreatic cancer were randomized (2: 1) to either 230 mg of LY2603618/1000 mg/m2 gemcitabine combined or 1000 mg/m2 gemcitabine alone. OS was assessed using both a Bayesian augment control model and traditional frequentist analysis for inference. Progression-free survival (PFS), overall response rate (ORR), duration of response, pharmacokinetics (PK), and safety (Common Terminology Criteria for Adverse Events [AEs] v 3.0) were also evaluated. Results: Ninety-nine patients (n = 65, LY2603618/gemcitabine; n = 34, gemcitabine) were randomized (intent-to-treat population). The median OS (months) was 7.8 (range, 0.3-18.9) with LY2603618/gemcitabine and 8.3 (range, 0.8-19.1+) with gemcitabine. Similarly, in a Bayesian analysis, the study was not positive since the posterior probability that LY2603618/gemcitabine was superior to gemcitabine in improving OS was 0.3, which did not exceed the prespecified threshold of 0.8. No significant improvements in PFS, ORR, or duration of response were observed. Drug-related treatment-emergent AEs in both arms included nausea, thrombocytopenia, fatigue, and neutropenia. The severity of AEs with LY2603618/gemcitabine was comparable to gemcitabine. The LY2603618 exposure targets (AUC((0-infinity)) >= 21,000 ng hr/mL and C-max >= 2000 ng/mL) predicted for maximum pharmacodynamic response were achieved after 230 mg of LY2603618. Conclusions: LY2603618/gemcitabine was not superior to gemcitabine for the treatment of patients with pancreatic cancer. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s12885-017-3131-x |
It is part of: | BMC Cancer, 2017, vol. 17, num. 137 |
URI: | http://hdl.handle.net/2445/124332 |
Related resource: | https://doi.org/10.1186/s12885-017-3131-x |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
LaquenteB.pdf | 585.04 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License